Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 7;124(8):1347–1355. doi: 10.1002/jso.26668

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Journal of Surgical Oncology published by Wiley Periodicals LLC

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Overall survival according to the sarcopenia, obesity, and sarcopenic obesity groups. (A) Sarcopenia versus non‐sarcopenia: all patients (p = 0.018). (B) Sarcopenia versus non‐sarcopenia: patients with stage I/II disease (p = 0.030). (C) Sarcopenia versus non‐sarcopenia: patients with stage III/IV disease (p = 0.945). (D) Obesity versus non‐obesity: all patients (p = 0.293). (E) Obesity versus non‐obesity: patients with stage I/II disease (p = 0.046). (F) Obesity versus non‐obesity: patients with stage III/IV disease (p = 0.825). (G) Sarcopenic obesity versus non‐sarcopenic obesity: all patients (p < 0.001). (H) Sarcopenic obesity versus non‐sarcopenic obesity: patients with stage I/II disease (p < 0.001). (I) Sarcopenic obesity versus non‐sarcopenic obesity: patients with stage III/IV disease (p = 0.392)